Genzyme to Build New R&D Center in Beijing

Environmentally Responsible Site to Significantly Increase Company's Presence in China

25-Apr-2008

Genzyme Corp. announced that it will build a major new research and development center in Beijing. The initiative is an important element in Genzyme's ongoing global expansion and commitment to establishing a long-term presence in China.

The new facility will be used for research and development activities involving many of Genzyme's key areas of focus, including orthopedics, transplant and immune disease, oncology, endocrinology and cardiovascular disease. The facility will include laboratory-scale operations for the MACI® (matrix-induced autologous chondrocyte implantation) cell therapy and polyclonal antibody operations.

"This new site represents a major step forward in our effort to improve the lives of patients in China by introducing innovative new medical products," said Henri A. Termeer, Genzyme's chairman and chief executive officer. "As we expand our presence in China, we look forward to making a significant contribution to the growth of the country's life sciences industry."

Genzyme's new Beijing facility will be located in Zhongguancun (ZGC) Life Science Park, an area dedicated to academic and government research centers as well as pharmaceutical and biotechnology companies. The 200,000 square-foot building will be constructed with low-impact environmental techniques and methods, and will incorporate a range of environmentally responsible features.

Genzyme is seeking necessary governmental authorizations and expects to complete and open the facility in 2010. The facility will be able accommodate 350 employees, and the total cost for the project is estimated to be $90 million.

https://www.analytica-world.com/en/news/81214/genzyme-to-build-new-r-d-center-in-beijing.html